Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹233 Cr
Revenue (TTM)
₹157 Cr
Net Profit (TTM)
₹18 Cr
ROE
10.5 %
ROCE
12.5 %
P/E Ratio
13.3
P/B Ratio
1.1
Industry P/E
26.59
EV/EBITDA
9.3
Div. Yield
0 %
Debt to Equity
0.1
Book Value
₹9
EPS
₹0.8
Face value
1
Shares outstanding
242,947,674
CFO
₹-16.73 Cr
EBITDA
₹68.52 Cr
Net Profit
₹54.13 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gennex Lab
| -32.9 | -14.4 | -32.3 | -28.0 | 16.3 | 20.6 | 1.8 |
|
BSE Healthcare
| -4.7 | -5.3 | -6.0 | 2.1 | 23.3 | 13.9 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Gennex Lab
| -16.6 | -5.3 | 163.1 | -42.2 | 123.7 | 83.9 | -29.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Gennex Lab
|
9.6 | 233.5 | 156.8 | 19.6 | 13.5 | 9 | 13.3 | 1.1 |
| 2,748.2 | 34,702.7 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.2 | 7.6 | |
| 7,759.5 | 19,400.0 | 2,177.5 | 200.9 | 11.3 | 26.5 | 96.6 | 23.3 | |
| 1,585.0 | 12,038.7 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.6 | 3.6 | |
| 1,485.0 | 9,055.7 | 1,196.4 | 149.4 | -- | 27.5 | 60.6 | 12.9 | |
| 1,313.7 | 18,244.7 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.3 | 5.0 | |
| 1,956.8 | 30,930.0 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41 | 7.7 | |
| 4,817.0 | 22,088.2 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.9 | 5.5 | |
| 4,885.0 | 8,038.4 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27.4 | 11.5 | |
| 986.5 | 9,099.8 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.8 | 3.1 |
No Review & Analysis are available.
Gennex Laboratories Limited engages in the manufacturing and selling of bulk drugs, intermediates, and biotech products in India and internationally. The company offers active pharmaceutical ingredients, including Guaifenesin; Methocarbamol;... Fluconazole; Phenazopyridine Hcl; Allopurinol; and Ketoconazole. Its pipeline products include Melitracen Hydrochloride; Flupentixol Di-Hydrochloride; Domperidone; Potassium Guaiacol Sulphonate; Mefenamic Acid; Melitracen; and Chlorphenesin. The company was formerly known as Prudential Pharmaceuticals Limited. Gennex Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India. Read more
Incorporated
1990
Chairman
--
Managing Director
Arihant Baid
Headquarters
Sangareddy, Telangana
Website
Looking for more details about Gennex Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Gennex Laboratories Ltd is ₹9.60 (BSE) as of 06-Apr-2026 13:14 IST. Gennex Laboratories Ltd has given a return of 16.25% in the last 3 years.
The P/E ratio of Gennex Laboratories Ltd is 13.26 times as on 06-Apr-2026, a 50 discount to its peers’ median range of 26.59 times.
The P/B ratio of Gennex Laboratories Ltd is 1.06 times as on 06-Apr-2026, a 76 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
15.12
|
1.51
|
|
2024
|
31.60
|
2.18
|
|
2023
|
16.00
|
1.24
|
|
2022
|
22.14
|
2.17
|
|
2021
|
11.69
|
1.25
|
The 52-week high and low of Gennex Laboratories Ltd are Rs 17.25 and Rs 7.05 as of 06-Apr-2026.
Gennex Laboratories Ltd has a market capitalisation of ₹ 233 Cr as on 06-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Gennex Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.19
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.